Latest News on ABBV

Financial News Based On Company


Advertisement
Advertisement

PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies

https://www.tradingview.com/news/zacks:1561f48db094b:0-pfe-inks-2-6b-licensing-deal-with-chinese-biotech-for-car-t-therapies/
Pfizer (PFE) has signed a $2.6 billion exclusive licensing deal with China's Starna Therapeutics for three investigational CAR-T programs targeting autoimmune diseases. This deal gives Pfizer rights outside Greater China to develop, manufacture, and commercialize these preclinical in vivo CAR-T therapies, with an upfront payment of $330 million and up to $2.3 billion in milestone payments. This move aligns with Pfizer's strategy to explore next-generation CAR-T therapies that modify T cells directly inside the patient's body, reducing complexities and costs associated with traditional CAR-T treatments.

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics

https://www.pharmaceutical-technology.com/news/abbvie-disco-partnership-bispecific-cancer-therapies/
AbbVie has entered a partnership with German biotech Disco Pharmaceuticals, valued at up to $2.5 billion, to develop bispecific cancer therapies for solid tumors. AbbVie will provide $40 million upfront and commit to additional milestones and royalties, securing an option to license therapies developed through the collaboration. The partnership will leverage Disco’s DISCOtech platform to design novel AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), aiming to broaden target ranges and reduce toxicity in solid tumor treatments.

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics

https://finance.yahoo.com/news/abbvie-disco-ink-2-5bn-153340392.html
AbbVie has partnered with German biotech Disco Pharmaceuticals in a deal potentially worth up to $2.5 billion, focusing on developing bispecific cancer therapies for solid tumors. AbbVie will pay $40 million upfront, with additional milestone payments and royalties, to leverage Disco's DISCOtech platform for designing selective bispecifics like AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). This collaboration aims to address unmet needs in solid tumor indications by developing therapies with a wider therapeutic window and reduced off-tumor toxicity.

3 ETFs That Hold AstraZeneca In Very Different Ways

https://simplywall.st/etfs/us/nysearca-ewu/news/3-etfs-that-hold-astrazeneca-in-very-different-ways
AstraZeneca's recent cancer treatment approval and high debt levels raise questions about its role in diversified portfolios. This article examines three ETFs—iShares MSCI United Kingdom ETF (EWU), Roundhill GLP-1 & Weight Loss ETF (OZEM), and JPMorgan Healthcare Leaders ETF (JDOC)—that hold AstraZeneca, each offering a different approach to balancing company-specific risks with broader market or sector exposure. Investors can choose between a broad UK market mix, a concentrated weight-loss drug focus, or a global healthcare industry spread.

DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B

https://www.pharmexec.com/view/disco-abbvie-sign-gated-bispecific-deal
DISCO Pharmaceuticals has signed a strategic collaboration and option-to-license agreement with AbbVie to develop AND-gated bispecific therapeutics for solid tumors. DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in milestones and royalties. This deal leverages DISCO's DISCOtech® surfaceome mapping platform to create therapies that selectively target tumor cells while minimizing harm to healthy tissue, building on a previous 2026 agreement with Amgen.
Advertisement

AbbVie Pays $2.54 Billion to Partner With Germany's Disco, Staking a Claim in Solid-Tumor Bispecific Antibodies

https://finance.biggo.com/news/d5aa9063-9e8d-4371-827c-847a96e23c7d
AbbVie has entered into an option and license agreement with Disco Pharmaceuticals, potentially worth up to $2.54 billion, to develop "AND-gated" bispecific antibodies for solid tumors. Disco will receive a $40 million upfront payment and milestone payments, focusing on research and discovery using its DiscoTech platform. This collaboration aims to create precision medicines that selectively target cancer cells while minimizing harm to healthy tissue, building on AbbVie's existing ventures in the bispecific antibody space.

Disco Pharma Partners With AbbVie to Develop Bispecific Therapies for Solid Tumors

https://www.genomeweb.com/business-news/deals/collaboration/gnw-disco-abbvie-collaboration-bispecifics-20261119/
Disco Pharma has partnered with AbbVie to develop bispecific therapies aimed at treating solid tumors. The collaboration seeks to advance innovative treatments in the field of cancer diagnostics and precision medicine. This strategic alliance was announced on November 19, 2026.

AbbVie to Invest $217 Million in Barceloneta Manufacturing Campus

https://www.wjournalpr.com/business/abbvie-to-invest-217-million-in-barceloneta-manufacturing-campus/article_cb164101-74d4-4204-8d51-68d87fb1cca9.html
AbbVie announced a $217 million investment to modernize its Barceloneta biologics manufacturing campus in Puerto Rico, incorporating advanced manufacturing technologies and artificial intelligence. This project is part of a broader $100 billion commitment to R&D and capital expenditures across the United States, creating 100 new jobs on the island. The modernization aims to strengthen production capabilities for current and next-generation medicines in immunology and neuroscience, with construction beginning this year and facilities fully operational by 2030.

AbbVie Signs $2.5B Bispecific Cancer Therapy Deal with Disco Pharma

https://www.globalbankingandfinance.com/abbvie-expands-bispecific-cancer-med-push-up-2-5-billion/
AbbVie has entered into an agreement with Disco Pharmaceuticals, potentially worth up to $2.54 billion, to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive an upfront payment of $40 million and could earn up to $2.5 billion in milestone payments and royalties. The collaboration focuses on "AND-gated" bispecific therapeutics designed to target cancer cells more precisely by recognizing two proteins simultaneously, thereby minimizing harm to healthy tissue.

AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

https://seekingalpha.com/news/4674531-abbvie-inks-up-to-254b-bispecific-cancer-drug-deal-with-disco-pharma
AbbVie has announced a collaboration with DISCO Pharmaceuticals, involving an upfront payment and potential milestone payments totaling up to $2.54 billion. This deal aims to develop new bispecific cancer treatments, expanding AbbVie's early-stage pipeline in this therapeutic area.
Advertisement

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://live.euronext.com/en/financial-news/abbvie-expands-bispecific-cancer-med-push-25-billion-deal-germanys-disco
AbbVie has entered into an agreement with Germany's Disco Pharmaceuticals, committing up to $2.54 billion to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, along with tiered royalties, for its AND-gated bispecific therapeutics. This early-stage collaboration focuses on developing treatments that target cancer cells only when two specific proteins are present simultaneously, aiming to minimize harm to healthy tissue.

AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal

https://www.biospace.com/business/abbvie-grooves-with-discos-solid-tumor-tech-in-up-to-2-5b-licensing-deal
AbbVie has partnered with DISCO Pharmaceuticals in a licensing deal potentially worth $2.54 billion for its logic-based bispecific platform to develop solid tumor therapies. AbbVie will provide a $40 million upfront payment, with the remainder contingent on milestones. This collaboration marks DISCO's second major pharma partnership this year, highlighting its DISCOtech platform for targeted therapies.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://www.reuters.com/legal/transactional/abbvie-expands-bispecific-cancer-med-push-with-up-25-billion-deal-with-germanys-2026-11-19/
AbbVie has agreed to a deal with Germany's Disco Pharmaceuticals worth up to $2.54 billion to develop next-generation bispecific cancer therapies. This collaboration focuses on "AND-gated" bispecific therapeutics for solid tumors, designed to target cancer cells more precisely by requiring the simultaneous presence of two target proteins. Disco will handle research and discovery, with AbbVie having exclusive licensing rights for further development.

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

https://finance.yahoo.com/healthcare/articles/disco-pharmaceuticals-announces-strategic-collaboration-070000264.html?.tsrc=rss
DISCO Pharmaceuticals has announced a strategic collaboration with AbbVie to develop novel AND-gated bispecific therapeutics for solid tumors. Under the agreement, DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in milestone payments and royalties. The collaboration leverages DISCO's DISCOtech® platform to identify tumor-selective target pairs, aiming to create therapies with a wider therapeutic window by selectively targeting tumor cells while sparing healthy tissue.

After Amgen, DISCO lands AbbVie deal worth up to $2.5B

https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/
Cologne-based DISCO Pharmaceuticals has secured a cancer drug discovery deal with AbbVie, involving an upfront payment of $40 million and potential additional payments of up to $2.5 billion. This marks DISCO's second major pharma partnership this year, building on its January agreement with Amgen. The collaboration focuses on DISCO's proprietary DISCOtech platform, which identifies cancer targets by mapping surfaceome proteins and using an AND-gating mechanism for improved tumor selectivity.
Advertisement

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

https://uk.finance.yahoo.com/news/disco-pharmaceuticals-announces-strategic-collaboration-070000806.html
DISCO Pharmaceuticals has announced a strategic collaboration with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors. Under the agreement, DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in milestone payments and royalties. This partnership aims to leverage DISCO's proprietary DISCOtech® platform to create highly selective precision medicines that target tumor cells while sparing healthy tissue.

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

https://www.globenewswire.com/news-release/2026/11/19/3406303/0/en/disco-pharmaceuticals-announces-strategic-collaboration-with-abbvie-to-advance-next-generation-and-gated-bispecific-therapeutics-for-solid-tumors.html
DISCO Pharmaceuticals announced a strategic collaboration and option-to-license agreement with AbbVie to develop novel AND-gated bispecific therapeutics for solid tumors. Under the agreement, DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in milestone payments, plus tiered royalties. This partnership leverages DISCO’s proprietary DISCOtech® platform to create precision medicines designed to selectively target tumor cells while sparing healthy tissue.

AbbVie COO Azita Saleki Executes Stock Options and Sells 13,481 Shares on November 16, 2026

https://kalkinemedia.com/us/news/announcements/abbvie-coo-azita-saleki-executes-stock-options-and-sells-13481-shares-on-november-16-2026
AbbVie Inc. EVP and Chief Operations Officer Azita Saleki executed stock options on November 16, 2026, acquiring 23,935 shares at $61.36 each. On the same day, she sold 13,481 shares at a weighted average price of $298.55, with individual sale prices ranging from $298.55 to $298.64. Following these transactions, Saleki directly held 208,248 shares and indirectly held an additional 2,764 shares through a profit-sharing trust.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco

https://kfgo.com/2026/11/19/abbvie-expands-bispecific-cancer-med-push-with-up-to-2-5-billion-deal-with-germanys-disco/
AbbVie has agreed to a deal worth up to $2.54 billion with Germany's Disco Pharmaceuticals to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, plus royalties, for its AND-gated bispecific therapeutics. This early-stage partnership aims to create treatments that specifically target cancer cells by requiring two proteins to be present simultaneously, thereby potentially reducing harm to healthy tissue.

AbbVie falls 2.31% in Wednesday's session

https://www.globalbankingandfinance.com/abbvie-abbv-falls-2026-11-18/
AbbVie shares experienced a 2.31% decline in Wednesday's trading session, closing at 286.07 USD. The company's market capitalization stood at $505.43 billion within the United States health care sector. This report was automatically generated from market data following the close of the trading session on November 18, 2026.
Advertisement

AbbVie Inc. stock underperforms Wednesday when compared to competitors

https://www.marketwatch.com/data-news/abbvie-inc-stock-underperforms-wednesday-when-compared-to-competitors-79033ee8-20a8a5a71eea
AbbVie Inc. (ABBV) stock fell 2.33% to $286.01 on Wednesday, experiencing its third consecutive day of losses. This underperformance occurred during a generally dismal trading session, with the S&P 500 Index and Dow Jones Industrial Average also declining. The company's stock lagged behind competitors on this particular day.

BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions

https://www.biospace.com/drug-development/bms-cobenfy-eases-alzheimers-psychosis-as-expected-but-safety-events-raise-questions
Bristol Myers Squibb (BMS) presented early data from its Phase 3 ADEPT program for Cobenfy (KarXT) at the CTAD conference, showing improvements in hallucinations and delusions in Alzheimer's disease psychosis patients. While efficacy signals were encouraging, analysts expressed concerns regarding the high rate of treatment-emergent adverse events (TEAEs) and discontinuations. The full randomized, placebo-controlled data, including relapse prevention, is expected in 2027 after previous delays.

AbbVie stock weekly forecast: Holds gains as buyers stay in control

https://tradersunion.com/news/stocks/show/4303756-abbvie-slips-0-76percent-over-the/
AbbVie (ABBV) shares are trading around $293, with buyers maintaining control despite a slight weekly dip. The company's neuroscience franchise saw significant growth, boosting its 2026 sales outlook, while new AI-driven drug discovery collaborations are expanding its pipeline. Technical indicators show mixed signals, with MACD in buy territory but Stochastic RSI suggesting potential selling exhaustion, setting up a potential range-bound week between $287.85 and $297.86.

Abbvie stock price target raised to $349 by Piper Sandler on growth

https://ca.investing.com/news/stock-market-news/abbvie-stock-price-target-raised-to-349-by-piper-sandler-on-growth-93CH-4966971
Piper Sandler has increased its price target for Abbvie (NYSE:ABBV) to $349 from $303, reiterating an Overweight rating. This adjustment reflects an attractive top-line and EBITDA growth profile expected through the end of the decade, driven by emerging visibility of Skyrizi combination products and the advancement of zumilokibart. Other analyst firms have also raised their price targets for Abbvie, citing strong performance in key segments like Rinvoq and Skyrizi, and promising pipeline developments.

Amazon, Marriott, Berkshire Hathaway And A Health Care Stock: CNBC’s ‘Final Trades’

https://www.benzinga.com/trading-ideas/long-ideas/26/11/63382508/amazon-marriott-berkshire-hathaway-and-a-health-care-stock-cnbcs-final-trades
On CNBC's "Halftime Report Final Trades," experts shared their top stock picks. Joshua Brown recommended Berkshire Hathaway, Rob Sechan picked Amazon.com due to its renewable energy investments in India, and Jason Snipe favored AbbVie Inc. following its strong Q3 results. Joseph M. Terranova suggested Marriott International, Inc. after the company also reported better-than-expected third-quarter financial results.
Advertisement

What Drove Glaukos Stock's 48% Rally Since the End of September?

https://www.tradingview.com/news/zacks:40817c3b2094b:0-what-drove-glaukos-stock-s-48-rally-since-the-end-of-september/
Glaukos (GKOS) stock has rallied 48% since September-end, primarily driven by stronger-than-expected third-quarter performance, which led to a significant increase in full-year sales guidance. Positive clinical developments for Epioxa and iDose TR, along with an expansion into the retinal pipeline, have further bolstered the company's growth outlook. The company is transitioning from a glaucoma-focused business to a broader ophthalmology platform, fueling investor confidence.

Amazon Stock Moves Higher: What's Going On?

https://www.benzinga.com/trading-ideas/movers/26/11/63395442/amazon-stock-moves-higher-whats-going-on-2
Amazon (NASDAQ:AMZN) shares are rising as investors anticipate the potential windfall from Amazon's stake in AI startup Anthropic, which is preparing for an IPO. Amazon has funded Anthropic with $18 billion and could own a substantial amount of stock after the IPO. Additionally, Anthropic has committed to significant cloud purchases from Amazon, providing a predictable revenue stream for Amazon’s cloud unit.

Abbvie (ABBV) PT Raised to $349 at Piper Sandler

https://www.streetinsider.com/Analyst+Comments/Abbvie+%28ABBV%29+PT+Raised+to+%24349+at+Piper+Sandler/27367137.html
Piper Sandler analyst David Amsellem has raised the price target for Abbvie (ABBV) to $349. The article, updated on November 18, 2026, also mentions the report from Piper Sandler. This is a premium article, requiring a subscription to read the full content.

FDA grants accelerated approval to GSK's Nelkarmi for lung cancer

https://www.streetinsider.com/Corporate+News/FDA+grants+accelerated+approval+to+GSKs+Nelkarmi+for+lung+cancer/27364693.html
The FDA has granted accelerated approval to GSK's Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). This approval applies to patients who have previously received specific ALK-targeted therapies, including those treated with alectinib as their only prior ALK TKI or those with two or more prior ALK TKIs plus platinum-based chemotherapy. The decision was based on positive results from the phase I/II ALKOVE-1 trial, demonstrating confirmed overall response rates and durable responses in both patient populations.

Merck stops trials of blood cancer drug after review of risks

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-stops-trials-blood-cancer-drug-after-risk-assessment-2026-11-17/
Merck has announced it will halt the development of its experimental blood cancer drug, nemtabrutinib, following a review that determined its benefits might not outweigh the associated risks. An independent monitoring committee made this recommendation after reviewing late-stage study results, a finding confirmed by Merck's own data analysis. This decision effectively ends the broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials.
Advertisement

AbbVie (ABBV) Taps AI Drug Discovery Partnership To Extend Its Research Pipeline

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-taps-ai-drug-discovery-partnership-to-extend-its
AbbVie (NYSE:ABBV) has formed an AI-driven drug discovery partnership with Iambic, aiming to use advanced algorithms to design and optimize early-stage clinical compounds. This collaboration expands AbbVie's research pipeline into next-generation AI-supported efforts, aligning with its strategy to refresh earnings as older drugs phase out. The success of this partnership will be measured by the progression of Iambic-designed assets into clinical trials and specific pipeline additions over the next few years.

CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics

https://www.manilatimes.net/2026/11/18/tmt-newswire/globenewswire/cytomx-therapeutics-announces-milestone-achievement-in-strategic-collaboration-with-regeneron-in-the-field-of-conditionally-activated-bispecifics/2472562
CytomX Therapeutics announced the achievement of a preclinical milestone in its collaboration with Regeneron, triggering a $5 million payment. This collaboration focuses on developing conditionally activated bispecific antibodies that target the tumor microenvironment, aiming to improve the therapeutic window and reduce side effects of T-cell engaging therapies. The partnership, which began in 2022 and expanded in June 2026, has the potential for CytomX to receive up to approximately $4 billion in milestone payments and tiered royalties.

Oncomine Assay Matches Standard Testing for Ovarian Cancer DNA Repair Deficiencies

https://bioengineer.org/oncomine-assay-matches-standard-testing-for-ovarian-cancer-dna-repair-deficiencies/
A new study found that the Oncomine Comprehensive Assay Plus (OCA Plus) effectively matches established companion diagnostics in identifying homologous recombination deficiency (HRD) in ovarian cancer samples, with an 86% overall concordance rate. This multi-gene platform can assess both molecular causes and genomic instability, potentially enabling decentralized HRD profiling and quicker diagnosis. While promising, the study's small cohort size and some diagnostic discrepancies highlight the need for larger, prospective studies to validate its routine clinical use and impact on treatment decisions.

How Did AbbVie's Neuroscience Franchise Perform in Q3?

https://www.tradingview.com/news/zacks:d592886f1094b:0-how-did-abbvie-s-neuroscience-franchise-perform-in-q3/
AbbVie's neuroscience segment experienced strong growth in Q3 2026, generating $3.39 billion in revenues, a 19.5% increase year-over-year. This performance, driven by drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, led AbbVie to raise its 2026 neuroscience sales outlook to $13 billion. The company also highlighted the potential of newly approved PD drug Juvmo and reiterated Vyalev's path to blockbuster status.

Final Trades: Berkshire Hathaway, Amazon, AbbVie and Marriott

https://www.cnbc.com/video/2026/11/17/final-trades-berkshire-hathaway-amazon-abbvie-marriott.html
The article features the "Investment Committee" providing their top stock picks for the second half of the year, including Berkshire Hathaway, Amazon, AbbVie, and Marriott. It is a brief announcement without further details on why these stocks were chosen. The content primarily highlights this segment and then lists other unrelated video snippets.
Advertisement

Natera Short Interest Rises As Bets Remain Near September Peak

https://www.benzinga.com/trading-ideas/short-ideas/26/11/63355238/natera-short-interest-rises-as-bets-remain-near-september-peak
Natera Inc. (NASDAQ:NTRA) saw its short interest rise by 3.77% to 6.07 million shares as of October 30, 2026, representing 4.31% of the float. This level is just below the September 30 peak of 6.36 million shares. The company's shares were down 3.22% at $279.18 on Tuesday, significantly below its 52-week high.

PR News | On the Move: Mars Snacking Names Belo Corp. Affairs Chief - Tue., Nov. 17, 2026

https://www.odwyerpr.com/story/public/25624/2026-11-17/move-mars-snacking-names-belo-corp-affairs-chief.html
This article details several significant personnel appointments in the public relations and marketing communications sector. Key moves include João Belo being named global VP of corporate affairs for Mars Snacking, Dave Anderson becoming CMO at BigPanda, Keith Schubert joining Rise and Shine and Partners as communication senior manager, and Tyler Holder becoming a shareholder at High Reason. The article also mentions other notable appointments at Teneo, INFINITE, Banc of California, and the PGA Tour.

AbbVie Is Up 27% in a Year. Barclays Sees Another 14%

https://www.tikr.com/blog/abbvie-is-up-27-in-a-year-barclays-sees-another-14?
Barclays has raised its price target for AbbVie (ABBV) to $335 from $325, maintaining an Overweight rating, following a 27% increase in the stock over the past year. This comes after AbbVie's strong third-quarter results, driven by significant revenue growth from Skyrizi and Rinvoq, and a raised 2026 earnings guidance. Despite some analysts holding a more conservative average target of $312, Barclays' bullish outlook implies a forward earnings multiple of 21x, which is higher than AbbVie's five-year peak.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

https://sg.finance.yahoo.com/news/invest-fidelity-msci-health-care-102003605.html
The Fidelity MSCI Health Care Index ETF (FHLC) offers diversified and low-cost exposure to the healthcare sector, making it an attractive option for long-term investors. With assets over $4.08 billion and an expense ratio of 0.08%, FHLC tracks the MSCI USA IMI Health Care Index. It currently holds a Zacks ETF Rank of 3 (Hold) and has shown a year-to-date gain of 21.32%.

OBI Pharma Signs Collaboration and License Agreement with Novartis

https://english.kyodonews.net/articles/-/91640
OBI Pharma has entered into a collaboration and license agreement with Novartis Pharma AG to develop next-generation Antibody-Drug-Conjugates (ADCs) using OBI's proprietary platform technologies. Under the agreement, Novartis gains exclusive worldwide rights to OBI's related patents for selected payload classes, and OBI will receive an upfront payment of USD 30 million, with potential milestone payments exceeding USD 2 billion, plus tiered royalties. This partnership aims to combine OBI's ADC expertise with Novartis's resources to advance innovative oncology therapies.
Advertisement

Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)

https://www.theglobeandmail.com/investing/markets/stocks/ABBV-N/pressreleases/8869866/barclays-reaffirms-their-buy-rating-on-abbvie-abbv/
Barclays has reiterated its Buy rating on AbbVie (ABBV), setting a price target of $335.00, with analyst Emily Field covering the Healthcare sector. This follows AbbVie's recent quarterly revenue of $17.4 billion and a net profit of $4.22 billion. Despite positive analyst ratings, corporate insider sentiment for ABBV is negative due to increased selling of shares over the past quarter.

Incyte says EU approves oral treatment for chronic skin disease

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/incyte-says-eu-approves-oral-treatment-for-chronic-skin-disease/135907602
The European Commission has approved Incyte's oral therapy, Povofortay (povorcitinib), for adults with moderate-to-severe hidradenitis suppurativa. This approval marks a potential new growth area for Incyte, aiming to diversify its portfolio beyond its blood cancer drug Jakafi. Povofortay works by blocking JAK1 and showed significant symptom improvement in late-stage studies.

Flagship Pioneering Puts £100 Million Into First Overseas Lab, Betting on AI Drug Discovery in London

https://finance.biggo.com/news/038e32c1-f578-4c48-8f66-d614eaeccf8d
Flagship Pioneering is investing an initial £100 million (about $131.9 million) to open its first company-creation lab outside the U.S. in London. The Flagship Origination Lab, U.K. will focus on building AI-native biotech companies, leveraging National Health Service patient data, and aims to attract an additional £500 million from partners. This move marks a significant expansion for the venture firm, which has previously operated solely from the U.S. and notably launched Moderna.

Acrivon Therapeutics Q3 Results: Loss narrows to $(0.42) per share

https://scanx.trade/stock-market-news/companies/acrivon-therapeutics-q3-results-loss-narrows-0-42-per-share/56420062
Acrivon Therapeutics reported a Q3 loss of $(0.42) per share, which beat the analyst consensus estimate of $(0.46) by 8.7%. This result signifies a 10.64% improvement in losses compared to the previous year's $(0.47) per share. The narrowing deficit suggests enhanced cost management or operational efficiency, surpassing market expectations.

Nxera Pharma: 2027 catalysts, the AbbVie deal and AI-led discovery underpin the growth agenda

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4641165:0-nxera-pharma-2027-catalysts-the-abbvie-deal-and-ai-led-discovery-underpin-the-growth-agenda/
Nxera Pharma is anticipating significant growth driven by multiple catalysts in 2027, including phase III data for direclidine and progress on cleminorexton. A strategic deal with AbbVie and its Japan portfolio are expected to support profitable expansion. Furthermore, the company aims to initiate lab testing for its first AI-designed molecules in the first quarter of 2027.
Advertisement

Independent Director Michael Miller Sold A Bunch Of Shares In Puma Biotechnology

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pbyi/puma-biotechnology/news/independent-director-michael-miller-sold-a-bunch-of-shares-i
Puma Biotechnology's Independent Director, Michael Miller, recently sold US$121k worth of stock at US$8.10 per share, reducing his holding by 28%. This was the largest insider sale in the last year, occurring at a price close to the current market value of US$7.77. While insiders own 14% of the company, valued at US$56m, the absence of recent insider buying and the pattern of selling suggest caution for potential investors.

How Investors Are Reacting To Nektar Therapeutics (NKTR) Phase 3 Trial Starts

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/how-investors-are-reacting-to-nektar-therapeutics-nktr-phase
Nektar Therapeutics (NKTR) has initiated Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, backed by a strong cash position of US$953 million and no debt. Despite current modest revenue and significant net losses, the company's investment narrative centers on the success of its Treg-focused REZPEG platform in large immunology indications. Analysts forecast a substantial swing to profitability by 2029, with potential upside to the current stock price contingent on trial execution and managing cash burn until key data readouts in 2028 and a planned BLA filing by late 2029.

OPHI - Expanding Distribution And Pipeline Advances Will Open New Markets

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-ophi/collplant-biotechnologies/zan48g5s-expanding-distribution-and-pipeline-advances-will-open-new-markets
CollPlant Biotechnologies (OPHI) is poised for future revenue growth through expanding distribution channels for its VergenixSTR product and promising preclinical studies on regenerative breast implants and a dermal filler. While strategic collaborations are expected to generate milestone payments, the company faces risks from increasing operational losses and dependence on these payments, which could impact financial stability. Analysts project substantial revenue growth but do not expect profitability within the next three years, with a consensus price target of $11.56.

Institutional Flow in AbbVie (ABBV): 67% of the Options Money Is in Calls

https://www.moomoo.com/community/feed/institutional-flow-in-abbvie-abbv-67-of-the-options-money-117622492823557
The article analyzes institutional options flow for AbbVie (ABBV), noting that 67% of the options premium, totaling $3.9M out of $5.7M, is in call options. It also details off-exchange (dark pool) share volumes and highlights a significant put contract expiring November 20. Key support levels for ABBV are provided, with the latest close at $295.03.

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/8835344/pfizers-59-yield-vs-abbvies-53-year-dividend-streak-which-stock-is-the-better-buy/
This article compares Pfizer (PFE) and AbbVie (ABBV) as investment options, particularly for income investors. Pfizer offers a high 5.9% dividend yield, making it attractive for maximizing cash flow, despite facing a patent cliff. AbbVie, a Dividend King with a 53-year dividend increase streak and a 2.5% yield, is presented as a better choice for investors seeking both income and growth, having successfully navigated its own patent cliff with strong new products.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement